1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
BioVie entered a sales agreement with A.G.P./Alliance Global Partners allowing it to sell up to $6,464,341 of Class A common stock through the agent over time. The company pays the agent a 3.0% commission on gross proceeds and says it may use proceeds for general corporate purposes; it has no obligation to sell any shares. Shareholders may face dilution if the shares are sold.
Aggregate offering price of up to $6,464,341 in Placement Shares under the Sales Agreement dated September 11, 2026
Agent commission of 3.0% of gross proceeds, plus reimbursement of certain specified expenses
Sales made under Form S-3 (File No. 333-296924), declared effective June 29, 2026; offering ends no later than the registration statement's third anniversary
Company has no obligation to sell shares and may suspend or terminate the offering at any time
Greenwave Technology Solutions closed a private placement of Series B Convertible Preferred Stock on September 9, 2026, raising $3.75 million before placement agent fees and other offering expenses. The preferred shares are convertible into common stock at an initial price of $5.24 per share, which creates potential dilution for existing common shareholders, and the company may not take certain actions, such as paying common dividends or issuing senior or parity preferred stock, without holder approval.
Closed September 9, 2026 with five institutional investors; aggregate proceeds of $3.75 million before fees and expenses
Authorizes 3,750 shares of Series B Preferred Stock, stated value $1,000 per share
Initial conversion price of $5.24 per share, with a 4.99% beneficial ownership cap on conversion
Holders have no voting rights except on certain matters affecting the preferred stock
GMR Solutions' subsidiary Global Medical Response, Inc. received binding lender commitments to reprice its existing first lien term loan, with closing expected on or about September 17, 2026. The company plans to prepay about $200 million from cash on hand, and expects roughly $28 million in annual cash interest savings, which supports its stated deleveraging goal.
Applicable margin falls from SOFR +325 to SOFR +275 basis points, a 50 basis point reduction
About $200 million of cash on hand to be used to repay term loan borrowings, reducing principal to about $2.7 billion from $2.9 billion
Expected annual cash interest savings of approximately $28 million
Closing expected on or about September 17, 2026, subject to customary conditions and definitive documentation
Sunshine Biopharma said that recent sales of its common stock under its at-the-market offering triggered a reduction in the exercise price of its outstanding Series B Warrants to $1.2046. The price is subject to further adjustment under the warrant terms. The change lowers the price at which warrant holders can buy shares, which could increase potential dilution for existing shareholders.
Series B Warrant exercise price reduced to $1.2046 per share
Reduction tied to recent sales of common stock under the at-the-market offering
Exercise price remains subject to further adjustment under the Series B Warrant terms
On September 9, 2026, Centrus Energy priced an underwritten offering of Class A common stock, pre-funded warrants and common warrants, with gross proceeds expected to be about $500 million before underwriting discount and expenses. Closing is expected on or about September 11, 2026, and the company said proceeds may fund working capital, technology, debt repayment, capital expenditures and acquisitions. The filing also discloses advanced talks on a potential acquisition of a domestic manufacturing supplier for about $115 million to $125 million, but no definitive agreement has been signed, and the new warrants could dilute existing shareholders if exercised.
Offering of 500,000 Class A shares, pre-funded warrants for 2,005,513 shares and common warrants for up to 6,992,382 shares, priced at a combined $199.64 per share
Gross proceeds expected to be about $500 million, before underwriting discount and other offering expenses; closing expected on or about September 11, 2026
Common warrants have four exercise price series from $226.8625 to $362.9800 per share
Company is in advanced discussions on a potential acquisition priced at about $115 million to $125 million; target generated about $160 million of revenue in 2025, and no definitive agreement has been signed
On September 4, 2026, Bonk, Inc. agreed to buy 26,667 of the 100,000 Series A Preferred Shares held by Core4 Capital Holdings Corp for $4.0 million, and disclosed the deal on September 11, 2026. As part of the deal, Core4 waived anti-dilution rights and its rights under the May 2, 2025 Certificate of Designation, including voting, liquidation preference and conversion rights, and agreed to a general release of claims. For shareholders, the filing shows a $4.0 million cash payment and a smaller preferred stake with fewer preferred rights, but no earnings or financial results.
Bonk will pay $4.0 million by wire within three business days of the September 4, 2026 agreement to purchase 26,667 preferred shares.
After the transaction, Core4 will hold 73,333 preferred shares, convertible into 1,516,873 common shares in a merger.
Core4 waived anti-dilution, voting, liquidation preference and conversion rights and agreed to a general release of claims against Bonk.
A subsidiary of Cardinal Infrastructure Group, Cardinal Civil Contracting, LLC, signed a second amendment to its credit agreement with Truist Bank and other lenders on September 10, 2026. The amendment adds a delayed draw term loan of up to $250 million and raises revolving commitments from $75 million to $100 million, giving the group more borrowing capacity under the facility.
Delayed draw term loan facility of up to $250,000,000 established under the Second Amendment
Aggregate revolving commitments increased from $75,000,000 to $100,000,000
Truist Bank serves as administrative agent, issuing bank and swingline lender; the parent company is not a party to the amendment or the Credit Agreement
On September 8, 2026, P3 Health Partners entered a Securities Purchase Agreement with affiliates of CPF to issue up to $70 million of units in multiple tranches, each including Series D-1 19.5% Cumulative Preferred Stock and warrants. A special committee of independent directors approved the deal because the CPF affiliates may be related parties. The preferred stock ranks senior to common stock, and the warrants could add to the number of common shares outstanding.
Up to $70 million of units to be issued in multiple tranches under a Securities Purchase Agreement dated September 8, 2026.
Series D-1 preferred stock: 19.5% cumulative dividend, $100 stated value per share, not convertible, no voting rights, redeemable at $100 per share plus unpaid dividends.
Warrants exercisable for 0.66333% of outstanding Class A and Class V common stock per $1,000,000 funded, with a seven-year term.
CPF may designate one additional independent director while it owns 40% of common stock; the 49.99% standstill limit is extended from January 1, 2027 to December 31, 2027.
Sphere 3D Corp. closed a $5.0 million private placement on September 11, 2026, selling 1,666,661 units at $3.00 each, with each unit including one common share and one warrant. The company also agreed to sell its non-core Iowa site and legacy mining fleet to fund AI and high-performance computing development. The new shares add dilution for existing shareholders, and the warrants could bring in about $5.8 million more if exercised for cash.
Private placement of 1,666,661 units at $3.00 per unit for $5.0 million in gross proceeds, closed September 11, 2026.
Each warrant has a $3.50 exercise price, is exercisable immediately, and expires five years after issuance.
Insiders, including the Chairman and CEO Joel Block, bought 333,332 units for about $1.0 million.
Iowa site sale for $1.5 million plus about $500,000 in deposit recovery; mining fleet sale for about $3 million; purchasers face a six-month lock-up.
Sandisk entered into Amendment No. 1 to its Loan Agreement on September 9, 2026, providing a $1.5 billion revolving credit facility that refinances the prior revolving commitments in full. The facility matures September 9, 2031, and carries a 1.375% margin on SOFR-based borrowings, which may step up or down based on leverage or credit ratings.
Revolving commitments of $1.5 billion replace prior revolving commitments under the Loan Agreement
Facility matures September 9, 2031, with no amortization
Pricing: SOFR plus 1.375% margin, or base rate plus 0.375%; commitment fee of 0.175% on undrawn amounts
Collateral and guarantees may be released if the company achieves certain investment grade corporate family ratings
USA Compression Partners priced a $600 million offering of 6.750% senior unsecured notes due 2035 at par, with net proceeds of about $592.1 million expected before the offering closes on or about September 18, 2026. The company plans to use the proceeds to repay outstanding borrowings under its credit agreement and to pay offering fees and expenses. The filing is a debt financing that refinances existing borrowings and does not report new operating results.
Notes: $600 million principal, 6.750% coupon, due 2035, sold at par
Estimated net proceeds: about $592.1 million after initial purchasers' discounts and offering expenses
Closing expected on or about September 18, 2026, subject to customary conditions
Proceeds to repay credit agreement borrowings; Issuers agreed to a 90-day lock-up on other debt sales
Nautilus Biotechnology entered a new Sales Agreement with TD Securities (USA), LLC (TD Cowen) that allows it to sell up to $125 million of common stock through an at-the-market offering, replacing a prior 2024 agreement with the same agent that the companies mutually terminated. The company has no obligation to sell any shares and can suspend sales at any time, but future sales would add new shares and dilute existing shareholders.
New Sales Agreement permits sales of up to $125,000,000 of common stock, to be issued under a shelf registration statement on Form S-3 once declared effective by the SEC.
TD Cowen would receive up to 3.0% of gross proceeds from any shares sold.
The prior Sales Agreement dated February 28, 2024 was mutually terminated on September 11, 2026; no shares were sold under it.
The company has no obligation to sell any shares and may suspend offers at any time.
Oaktree Specialty Lending Corporation entered into an underwriting agreement on September 9, 2026 to issue $300.0 million of 7.000% Notes due 2031. The company expects net proceeds of $296.5 million, with closing expected on September 16, 2026, subject to customary conditions. The debt issuance adds funding capacity and adds to the company's debt obligations.
Principal amount: $300.0 million of 7.000% Notes due 2031
Underwriting agreement dated September 9, 2026 with J.P. Morgan Securities LLC and other underwriters
Net proceeds expected to be $296.5 million after a $2.6 million underwriting discount and about $0.8 million in offering expenses
Closing expected September 16, 2026, subject to customary closing conditions
On September 11, 2026, Caring Brands completed an additional closing of its private placement of Series B Convertible Preferred Stock, raising $2,549,900 in gross proceeds and bringing the offering total to $7,149,900. The company says pro forma stockholders' equity of $8,220,419 as of August 31, 2026 is above the $2,500,000 Nasdaq minimum, but the figures are preliminary and unaudited, and Nasdaq has not confirmed compliance.
Subsequent closing on September 11, 2026 added $2,549,900 in gross proceeds; total offering proceeds are $7,149,900.
Preferred shares from the closing are initially convertible into 3,642,714 common shares at $0.70 per share, subject to a 19.99% exchange cap.
Pro forma stockholders' equity is $8,220,419 versus a historical deficit of $2,632,167 at August 31, 2026, against a Nasdaq minimum of $2,500,000.
Nasdaq has not confirmed compliance; the company has asked the Nasdaq Hearings Panel to resolve the deficiency after a July 15, 2026 delisting determination.
Hudson Pacific Properties and its joint venture partner extended the $1.1 billion CMBS loan secured by the Hollywood Media Portfolio to November 9, 2027, with no principal paydown required and the stated interest rate unchanged. The agreement also sets aside a $20 million reserve for leasing and capital improvements, with future excess cash flow swept into that reserve, which the company says removes near-term maturity risk.
Loan maturity moved to November 9, 2027; agreement dated September 9, 2026
No principal repayment required and stated interest rate unchanged
$20 million leasing and capital improvement reserve funded at closing, with excess cash flow swept into it
Hudson Pacific owns a 51% interest in the 2.2 million-square-foot portfolio and oversees its operations
Oklo entered a new equity distribution agreement allowing it to sell up to $1,000,000,000 of Class A common stock through nine sales agents. It ended a prior $1 billion program dated May 13, 2026, which it terminated effective September 10, 2026, after selling 17,971,448 shares for gross proceeds of approximately $1,000,000,000. For shareholders, the new agreement gives Oklo capacity to issue more shares, which would increase the number of shares outstanding.
New agreement dated September 11, 2026 with Goldman Sachs, BofA Securities, Citigroup, J.P. Morgan, Morgan Stanley, Barclays, Cantor Fitzgerald, Guggenheim, Canaccord Genuity and B. Riley Securities allows sales of up to $1,000,000,000 in g
Oklo will pay the sales agents a commission of up to 1.5% of the gross sales price of shares sold.
Prior agreement dated May 13, 2026 was terminated effective close of business September 10, 2026, with no termination penalties, after 17,971,448 shares were sold for about $1,000,000,000.
Shares will be issued under shelf registration on Form S-3 (File No. 333-291157); the filing does not report any sales under the new program.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.